Cardiovascular safety of second-generation antihistamines

Jean Thierry Barbey, Mark Anderson, Giorgio Ciprandi, Anthony J. Frew, Martin Morad, Silvia G. Priori, Ennio Ongini, Melton B. Affrime

Research output: Contribution to journalArticle

33 Citations (Scopus)

Abstract

Reports of serious cardiac arrhythmia associated with some second- generation antihistamines have prompted concern for their prescription. This article reviews the nature of the adverse events reported and concludes that the blockade of potassium channels, particularly the subtype responsible for the rapid component of the delayed rectifier current (I(Kr)), is largely responsible for such adverse cardiac events. Consequently, antihistamines with little or no interaction with these channels are expected to have the greatest safety margin. The main cardiac arrhythmia of concern is that of torsades de pointes, a potentially fatal phenomenon characterized by prolonged ventricular depolarization that manifest as a prolonged QT interval and polymorphic ventricular tachycardia, with twisting of the QRS complexes. Based on preclinical and clinical evidence, it appears that loratadine, cetirizine, and fexofenadine are safe from cardiac arrhythmia via the I(Kr) channel, whereas astemizole and terfenadine have a propensity to cause ventricular tachyarrhythmias.

Original languageEnglish
Pages (from-to)235-243
Number of pages9
JournalAmerican Journal of Rhinology
Volume13
Issue number3
Publication statusPublished - 1999

Fingerprint

Non-Sedating Histamine H1 Antagonists
Cardiac Arrhythmias
fexofenadine
Safety
Astemizole
Loratadine
Cetirizine
Terfenadine
Torsades de Pointes
Histamine Antagonists
Potassium Channels
Ventricular Tachycardia
Tachycardia
Prescriptions

ASJC Scopus subject areas

  • Otorhinolaryngology

Cite this

Barbey, J. T., Anderson, M., Ciprandi, G., Frew, A. J., Morad, M., Priori, S. G., ... Affrime, M. B. (1999). Cardiovascular safety of second-generation antihistamines. American Journal of Rhinology, 13(3), 235-243.

Cardiovascular safety of second-generation antihistamines. / Barbey, Jean Thierry; Anderson, Mark; Ciprandi, Giorgio; Frew, Anthony J.; Morad, Martin; Priori, Silvia G.; Ongini, Ennio; Affrime, Melton B.

In: American Journal of Rhinology, Vol. 13, No. 3, 1999, p. 235-243.

Research output: Contribution to journalArticle

Barbey, JT, Anderson, M, Ciprandi, G, Frew, AJ, Morad, M, Priori, SG, Ongini, E & Affrime, MB 1999, 'Cardiovascular safety of second-generation antihistamines', American Journal of Rhinology, vol. 13, no. 3, pp. 235-243.
Barbey JT, Anderson M, Ciprandi G, Frew AJ, Morad M, Priori SG et al. Cardiovascular safety of second-generation antihistamines. American Journal of Rhinology. 1999;13(3):235-243.
Barbey, Jean Thierry ; Anderson, Mark ; Ciprandi, Giorgio ; Frew, Anthony J. ; Morad, Martin ; Priori, Silvia G. ; Ongini, Ennio ; Affrime, Melton B. / Cardiovascular safety of second-generation antihistamines. In: American Journal of Rhinology. 1999 ; Vol. 13, No. 3. pp. 235-243.
@article{91c1d34be20f4995b964fcb7d388b370,
title = "Cardiovascular safety of second-generation antihistamines",
abstract = "Reports of serious cardiac arrhythmia associated with some second- generation antihistamines have prompted concern for their prescription. This article reviews the nature of the adverse events reported and concludes that the blockade of potassium channels, particularly the subtype responsible for the rapid component of the delayed rectifier current (I(Kr)), is largely responsible for such adverse cardiac events. Consequently, antihistamines with little or no interaction with these channels are expected to have the greatest safety margin. The main cardiac arrhythmia of concern is that of torsades de pointes, a potentially fatal phenomenon characterized by prolonged ventricular depolarization that manifest as a prolonged QT interval and polymorphic ventricular tachycardia, with twisting of the QRS complexes. Based on preclinical and clinical evidence, it appears that loratadine, cetirizine, and fexofenadine are safe from cardiac arrhythmia via the I(Kr) channel, whereas astemizole and terfenadine have a propensity to cause ventricular tachyarrhythmias.",
author = "Barbey, {Jean Thierry} and Mark Anderson and Giorgio Ciprandi and Frew, {Anthony J.} and Martin Morad and Priori, {Silvia G.} and Ennio Ongini and Affrime, {Melton B.}",
year = "1999",
language = "English",
volume = "13",
pages = "235--243",
journal = "American Journal of Rhinology",
issn = "1050-6586",
publisher = "OceanSide Publications Inc.",
number = "3",

}

TY - JOUR

T1 - Cardiovascular safety of second-generation antihistamines

AU - Barbey, Jean Thierry

AU - Anderson, Mark

AU - Ciprandi, Giorgio

AU - Frew, Anthony J.

AU - Morad, Martin

AU - Priori, Silvia G.

AU - Ongini, Ennio

AU - Affrime, Melton B.

PY - 1999

Y1 - 1999

N2 - Reports of serious cardiac arrhythmia associated with some second- generation antihistamines have prompted concern for their prescription. This article reviews the nature of the adverse events reported and concludes that the blockade of potassium channels, particularly the subtype responsible for the rapid component of the delayed rectifier current (I(Kr)), is largely responsible for such adverse cardiac events. Consequently, antihistamines with little or no interaction with these channels are expected to have the greatest safety margin. The main cardiac arrhythmia of concern is that of torsades de pointes, a potentially fatal phenomenon characterized by prolonged ventricular depolarization that manifest as a prolonged QT interval and polymorphic ventricular tachycardia, with twisting of the QRS complexes. Based on preclinical and clinical evidence, it appears that loratadine, cetirizine, and fexofenadine are safe from cardiac arrhythmia via the I(Kr) channel, whereas astemizole and terfenadine have a propensity to cause ventricular tachyarrhythmias.

AB - Reports of serious cardiac arrhythmia associated with some second- generation antihistamines have prompted concern for their prescription. This article reviews the nature of the adverse events reported and concludes that the blockade of potassium channels, particularly the subtype responsible for the rapid component of the delayed rectifier current (I(Kr)), is largely responsible for such adverse cardiac events. Consequently, antihistamines with little or no interaction with these channels are expected to have the greatest safety margin. The main cardiac arrhythmia of concern is that of torsades de pointes, a potentially fatal phenomenon characterized by prolonged ventricular depolarization that manifest as a prolonged QT interval and polymorphic ventricular tachycardia, with twisting of the QRS complexes. Based on preclinical and clinical evidence, it appears that loratadine, cetirizine, and fexofenadine are safe from cardiac arrhythmia via the I(Kr) channel, whereas astemizole and terfenadine have a propensity to cause ventricular tachyarrhythmias.

UR - http://www.scopus.com/inward/record.url?scp=0033005063&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0033005063&partnerID=8YFLogxK

M3 - Article

VL - 13

SP - 235

EP - 243

JO - American Journal of Rhinology

JF - American Journal of Rhinology

SN - 1050-6586

IS - 3

ER -